Title
Author
DOI
Article Type
Special Issue
Volume
Issue
The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?
1Division of Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy
*Corresponding Author(s): A. Martoni E-mail:
A phase I study was performed in order to evaluate the tolerability of the combination of fixed doses of carboplatin and paclitaxel and escalated doses of topotecan as first line chemotherapy for advanced epithelial ovarian cancer. Three stage III and one stage IV patients entered the study. The dose limiting toxicity (neutropenia and thrombocytopenia) was reached at the first dose level: paclitaxel 175 mg/m2 on day 1, carboplatin AUC 5 on day I and topotecan 0.5 mg/m2 daily from day 1 to day 3. We conclude that it is not possible to add topotecan to standard regimens of carboplatin and paclitaxel without bone marrow support.
Topotecan; Paclitaxel; Carboplatin; Polychemotherapy; Ovarian cancer
N. Cacciari,C. Zamagni,A. Martoni. The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?. European Journal of Gynaecological Oncology. 2000. 21(1);84-85.
[1] ten Bokkel Huinink W. W. Gore M., Carmichael J. et al.: "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oneal., 1997, 15, 2183.
[2] Zamagni C., Martoni A., Cacciari N., Gentile A. and Pannuti F.: "The combination of paclitaxel and carboplatin as first line chemotherapy in patients with stage III and IV ovarian cancer: a phase I-II study". Am. J. Clin. Oneal., 1998, 21, 491.
[3] Armstrong D. K., O'Reilly S., Bookman M. et al.: "A phase I study of topotecan, cisplatin and paclitaxel in newly diagnosed epithelial ovarian cancer, a Gynecologic Oncology Group (GOG 9602) study". Proceedings of ASCO, 17 (abst. 1351) 1998.
[4] ten Bokkel Huinink W.W., Richel D. J., Herben V. M. M. et al.: "Feasibility study of the combination of cisplatin, paclitaxel and topotecan in ovarian cancer patients". Proceedings of ASCO 17 (abst. 1353) 1998.
[5] Schilder R. J., Gallo J.M., Johnson S. W. et al.: "Phase I study of multiple cycles of high dose topotecan, carboplatin and paclitaxel with peripheral blood stem cell support". Proceedings of ASCO 17 (abst. 290) 1998.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top